NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Forecast & News

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings data on Friday, March, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.

Press coverage about GEMP stock has been trending positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Gemphire Therapeutics.

Some companies that are related to Gemphire Therapeutics include Clovis Oncology (CLVS), Ardelyx (ARDX), Sinovac Biotech (SVA), Viking Therapeutics (VKTX), OrganiGram (OGI), Arcus Biosciences (RCUS), Organogenesis (ORGO), Dynavax Technologies (DVAX), Assembly Biosciences (ASMB), Axovant Sciences (AXON), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHYF), Catalyst Pharmaceuticals (CPRX), Aptorum Group (APM) and Rigel Pharmaceuticals (RIGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Pixelworks (PXLW), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Nektar Therapeutics (NKTR), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Melinta Therapeutics (MLNT).

(GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GEMP stock can currently be purchased for approximately $8.35.

Gemphire Therapeutics has a market capitalization of $124.16 million. Gemphire Therapeutics employs 9 workers across the globe.View Additional Information About Gemphire Therapeutics.

The official website for Gemphire Therapeutics is http://www.gemphire.com/.

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]